AGM 2020 Presentation

November 18, 2020August 16, 2022 Alterity Therapeutics

2020

Post navigation

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
XBRL 30 June 2022 filed with the SEC
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Appendix 4C – Q4 FY22 Quarterly Cash Flow Report
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

AGM 2020 Presentation

Related Posts

Alterity CEO David Stamler presents to US investors at the HC Wainwright Global Life Science Conference

Appendix 4C – Q4 FY22 Quarterly Cash Flow Report

Prana Shows Significant Promise in the Fight Against Alzheimer’s Disease According to Experts at Celebration of Science Conference